Also Notable

• Advantage Tear Diagnostics launched the point-of-care tear testing instrument, TearScan300, which takes a patient tear sample and determines levels of lactoferrin (an indicator of dry eye) and IgE (an indication of allergy).
• Alcon announced that Pataday Once Daily Relief (olopatadine hydrochloride ophthalmic solution 0.2%) and Pataday Twice Daily Relief (olopatadine hydrochloride ophthalmic solution 0.1%) have been FDA approved for OTC sale in the United States.
• Carl Zeiss Meditec’s Jim Mazzo, global president of ophthalmic devices, announced his retirement, effective May 1. He will continue as an advisor and will be succeeded by Dr. Euan Thomson, who will manage both the global Ophthalmics and Digital Business Units.
• CooperVision has become a Global Patron of the International Agency for the Prevention of Blindness (IAPB). The company and IAPB will collaborate to bring greater awareness and action to the growing prevalence and severity of global childhood myopia.
• Eyevance Pharmaceuticals appointed Julie Speed to chief commercial officer. She will be responsible for developing the commercial strategy and overseeing the growth of Eyevance’s product portfolio.
• Harrow Health and wholly-owned subsidiary ImprimisRx announced an exclusive agreement with Doxy.me , a telemedicine solution. The agreement will provide ImprimisRx ophthalmology, optometry and wellness practices with the clinic-level Doxy.me solution at no charge. For information, visit https://www.imprimisrx.com/telemed/ .
• The International Sports Vision Association (ISVA) has announced the appointments of Jennifer Stewart, O.D., and Todd Daniels, MS, ATC, LMT, CSCS, to its advisory board.
• Leo Lens Pharma has received a notice of allowance from the U.S. Patent and Trademark Office for its proprietary MediPrint process to manufacture a contact lens for myopia management that continuously delivers a drug, such as low-dose atropine, to the eye.
• The Neuro-Optometric Rehabilitation Association and the Concussion Legacy Foundation developed Common Vision Problems & Symptoms Following a Concussion. See: https://bit.ly/2IChHCm .
• PentaVision’s* Contact Lens Spectrum magazine partnered with organizations across the world — including the International Association of Contact Lens Educators and the British Contact Lens Association — to better understand the issues surrounding contact lenses. Consider filling out this five-minute survey to weigh in: https://forms.gle/7gPWKQemgnivZ6oH8 . *PentaVision also publishes Optometric Management.
• SUNY College of Optometry will take part in a multi-center U.S. clinical trial sponsored by Eyenovia, Inc. to evaluate the safety and effectiveness of MicroPine, an atropine eye solution meant to slow myopia progression in children ages 3 to 12.
• Verily, a subsidiary of Alphabet (Google) focused on life sciences and healthcare, partnered with Santen Pharmaceutical Co. to create and commercialize ophthalmic devices and comprehensive tech-enabled solutions to develop more preventive and proactive solutions regarding eye health.
• Visioneering Technologies, Inc. has received a Medical Device License from Health Canada, allowing VTI to market and sell its products in Canada. The license covers the use of the company’s NaturalVue Multifocal contact lens for the control of myopia progression, according to the company. OM